#TcellEngager - Twitter Hashtag

9 months ago

#OnlineFirst: Identification and Non-clinical Characterization of SAR444200, a Novel Anti-GPC3 #NANOBODY® T-cell Engager, for the Treatment of #GPC3+ #SolidTumors https://t.co/yY6fcatHz9 @sanofi #FirstDisclosure #TCellEngager #OpenAccess

MCT_AACR's tweet photo. #OnlineFirst: Identification and Non-clinical Characterization of SAR444200, a Novel Anti-GPC3 #NANOBODY® T-cell Engager, for the Treatment of #GPC3+ #SolidTumors https://t.co/yY6fcatHz9
@sanofi #FirstDisclosure #TCellEngager #OpenAccess https://t.co/MsLt1sAsnE

0

3

0

263

abpro @Abpro

about 1 year ago

Abpro unveiled preclinical data for ABP-102/CT-P72 at #AACR25. This HER2 x CD3 #TCellEngager showed potent tumor killing, reduced cytokine release & improved tolerability—supporting its potential as best-in-class. More info: https://t.co/KRY6n294Dk $ABP

Abpro's tweet photo. Abpro unveiled preclinical data for ABP-102/CT-P72 at #AACR25. This HER2 x CD3 #TCellEngager showed potent tumor killing, reduced cytokine release & improved tolerability—supporting its potential as best-in-class.

More info: https://t.co/KRY6n294Dk

$ABP https://t.co/CTXCnEBRLu

1

7

1

0

582

Course5 Life Sciences @Course5_LifeSci

almost 4 years ago

#ESMO22 Updates: IMC-F106C (PRAME×CD3) show encouraging responses in heavily pre-treated pts esp. in cutaneous and uveal melanoma – represents larger opportunities for development and further validation #solidtumors #oncology #immunotherapy #tcellengager #bispecifics

Course5_LifeSci's tweet photo. #ESMO22 Updates: IMC-F106C (PRAME×CD3) show encouraging responses in heavily pre-treated pts esp. in cutaneous and uveal melanoma – represents larger opportunities for development and further validation
#solidtumors #oncology #immunotherapy #tcellengager #bispecifics https://t.co/nhc9YNQUOy

0

6

2

0

Numab Therapeutics @Numab_Tx

over 4 years ago

Numab will present novel preclinical data on its #ROR1-targeting antibody NM32-2668 at #SITC2021. Check out the SITC website or our website on Friday November 12th to learn more about the tri-specific ROR1xCD3xHSA #TcellEngager.

Numab_Tx's tweet photo. Numab will present novel preclinical data on its #ROR1-targeting antibody NM32-2668 at #SITC2021. Check out the SITC website or our website on Friday November 12th to learn more about the tri-specific ROR1xCD3xHSA #TcellEngager. https://t.co/WajMQakSgO

0

1

0

Bernard A Fox @BernardAFox

almost 5 years ago

💥Hats off to @DanChenMDPhD! Great talk & Amazing job driving panel discussion @sitcancer #TCellEngager #TCE #DART #TCB #BiTEs Workshop. Great fun participating on panel with Dan and Dr Rafi Ahmed! Almost felt like we were in the same room! ONLY 41 DAYS UNTIL SITC! #FinishCancer

BernardAFox's tweet photo. 💥Hats off to @DanChenMDPhD! Great talk & Amazing job driving panel discussion @sitcancer #TCellEngager #TCE #DART #TCB #BiTEs Workshop. Great fun participating on panel with Dan and Dr Rafi Ahmed! Almost felt like we were in the same room! ONLY 41 DAYS UNTIL SITC! #FinishCancer https://t.co/GSUBvGBYSV

1

9

0

LARVOL

@Larvol

almost 5 years ago

Breaking news out of @Amgen today 🚨 https://t.co/2UiZAWw4K1 #biotech #MultipleMyeloma #bispecifics #tcellengager #clinicaltrial

9

3

0

Erin Meermeier PhD @erinmeermeier

almost 5 years ago

Thank you to @BCD_AACR for creating this cover art featuring our research #Tcellengager #greekmythology

Acquired Resistance to Therapy Network (ARTNet)

@NCIARTNet

almost 5 years ago

@DRSNmoonshot PIs @Leif_Bergsagel,@erinmeermeier & team @MayoClinic work features "on the cover" @BCD_AACR -responses to bispecific T-cell engager (BiTE) antibody therapy of myeloma, limited by T cell exhaustion can be overturned by adding cyclophosphamide https://t.co/AidIiDrZ9r

NCIARTNet's tweet photo. @DRSNmoonshot PIs @Leif_Bergsagel,@erinmeermeier & team @MayoClinic work features "on the cover" @BCD_AACR -responses to bispecific T-cell engager (BiTE) antibody therapy of myeloma, limited by T cell exhaustion can be overturned by adding cyclophosphamide https://t.co/AidIiDrZ9r https://t.co/oKOOyzkk1P

0

4

3

0

2

4

1

0

Cancer Immunology Research @CIR_AACR

over 5 years ago

ICYMI: Read here about a #bispecific #antibody that can unleash #γδTcell–mediated #AntitumorResponses against both #leukemia and #MultipleMyeloma. #CD40 #TcellEngager https://t.co/6xVGWucgkv

CIR_AACR's tweet photo. ICYMI: Read here about a #bispecific #antibody that can unleash #γδTcell–mediated #AntitumorResponses against both #leukemia and #MultipleMyeloma.
#CD40 #TcellEngager
https://t.co/6xVGWucgkv https://t.co/MwD3up03rf

0

1

0

Cancer Immunology Research @CIR_AACR

over 5 years ago

Read here about a #bispecific #antibody that can unleash #γδTcell–mediated #AntitumorResponses against both #leukemia and #MultipleMyeloma. #CD40 #TcellEngager https://t.co/ZjnP9l4xHu

CIR_AACR's tweet photo. Read here about a #bispecific #antibody that can unleash #γδTcell–mediated #AntitumorResponses against both #leukemia and #MultipleMyeloma.
#CD40 #TcellEngager
https://t.co/ZjnP9l4xHu https://t.co/r5xoTjAegY

0

2

1

0

Marseille Immunopole @Immunopole

over 8 years ago

#ImmuneCheckpoint inhibitors, #TCellEngager #antibodies #CART: new types of immunotherapies for the management of patients with lymphoma @Annals_Oncology https://t.co/TO2XmTm1RA

Immunopole's tweet photo. #ImmuneCheckpoint inhibitors, #TCellEngager #antibodies #CART: new types of immunotherapies for the management of patients with lymphoma @Annals_Oncology https://t.co/TO2XmTm1RA https://t.co/ibEgUtLHC2

0

2

6

0

Top Tweets for #TcellEngager

Last Seen Hashtags on Sotwe

Trends for you

Most Popular Users